{"organizations": [], "uuid": "cdb246ea634676e85c73dad0abbe3a86ff75d5a5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180405.html", "section_title": "Archive News &amp; Video for Thursday, 05 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-casi-pharma-says-advisory-committe/brief-casi-pharma-says-advisory-committee-to-review-evomela-between-april-25-26-idUSASC09V0Z", "country": "US", "domain_rank": 408, "title": "BRIEF-CASI Pharma Says Advisory Committee to Review Evomela Between April 25-26", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.035, "site_type": "news", "published": "2018-04-05T20:18:00.000+03:00", "replies_count": 0, "uuid": "cdb246ea634676e85c73dad0abbe3a86ff75d5a5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-casi-pharma-says-advisory-committe/brief-casi-pharma-says-advisory-committee-to-review-evomela-between-april-25-26-idUSASC09V0Z", "ord_in_thread": 0, "title": "BRIEF-CASI Pharma Says Advisory Committee to Review Evomela Between April 25-26", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "casi pharmaceuticals inc", "sentiment": "negative"}, {"name": "brief-casi pharma says advisory committee", "sentiment": "negative"}, {"name": "asi pharmaceuticals", "sentiment": "none"}, {"name": "casi pharmaceuticals inc - advisory committee", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 5 (Reuters) - CASI Pharmaceuticals Inc:\n* CASI PHARMACEUTICALS PROVIDES UPDATE ON EVOMELAÂ® * CASI PHARMACEUTICALS - RECEIPT OF LETTER FROM CENTER FOR DRUG EVALUATION FOR INJECTION SCHEDULED FOR REVIEW BY ADVISORY COMMITTEE\n* CASI PHARMACEUTICALS INC - ADVISORY COMMITTEE MEETING SCHEDULED TO TAKE PLACE BETWEEN APRIL 25-26, 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-05T20:18:00.000+03:00", "crawled": "2018-04-06T21:46:55.002+03:00", "highlightTitle": ""}